Table 1.

Disposition of Japanese patients from the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 studies

n (%)	KEYNOTE-059	KEYNOTE-061		KEYNOTE-062
	All patients	CPS ≥ 1		CPS ≥ 1
	Pembrolizumab	Pembrolizumab	Chemotherapy	Pembrolizumab	Chemotherapy
	n = 34	n = 27	n = 38	n = 38	n = 32
Status for trial
Discontinued	31 (91)	21 (78)	35 (92)	24 (63)	25 (78)
Death	31 (91)	21 (78)	34 (90)	24 (63)	25 (78)
Protocol violation	0	0	1 (3)	0	0
Ongoing	3 (9)	6 (22)	3 (8)	14 (37)	7 (22)
Status for study treatment
Discontinued		25 (93)	36 (100)	36 (95)	31 (97)
AE	—	0	1 (3)	3 (8)	2 (6)
Clinical progression	—	3 (11)	3 (8)	6 (16)	1 (3)
Progressive disease	—	22 (82)	32 (89)	25 (66)	25 (78)
Noncompliance	—	0	0	1 (3)	1 (3)
Withdrawal by patient	—	0	0	1 (3)	2 (6)
Ongoing	—	1 (4)	0	1 (3)	1 (3)

AE adverse events, CPS combined positive score